Camurus股价上涨,因第二季度营收和营业利润超出预期

路透中文
Jul 15
BUZZ-Camurus股价上涨,因第二季度营收和营业利润超出预期

7月15日 - ** 瑞典生物技术公司Camurus(CAMX.ST)公布 (link) 第二季度业绩超出预期后,其股价上涨10%

** 其营收达到7.02亿瑞典克朗(7280万美元),高于IBES预估的6.328亿瑞典克朗

** 杰富瑞表示,营收超预期主要得益于注射用阿片类药物使用障碍治疗药物Brixadi和Buvidal的销售,此外与礼来公司合作获得的500万美元里程碑付款 LLY.N 已“计入财报”

** 本季度营业利润为2.93亿瑞典克朗,高于IBES预估的2.32亿瑞典克朗

** 杰富瑞指出,营收增长、符合预期的毛利率以及运营费用共同推动了营业利润超出预期

** 杰富瑞预计,Camurus将在今年第四季度前就其激素紊乱治疗药物Oclaiz向美国食品药品监督管理局(FDA)重新提交 (link) 的申请

** GMT 07:01,股价上涨10%,若涨势得以维持,这将是该股自2025年11月以来表现最佳的一天

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10